Projected Outcomes of Reducing Federal Funding for Syringe Service Programs via Executive Order - Top-Institutions - MDSpire

Projected Outcomes of Reducing Federal Funding for Syringe Service Programs via Executive Order

  • By

  • Kirk B. Fetters

  • Pranav Padmanabhan

  • Kristina Yamkovoy

  • Xiaoyu Guan

  • Sarah E. Scott

  • Lauren Kerr

  • Kathleen Joseph

  • Gwenyth L. Day

  • Marina Plesons

  • Tyler S. Bartholomew

  • Hansel E. Tookes

  • Alia Al-Tayyib

  • Joshua A. Barocas

  • June 18, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Public Health
    • Harm Reduction

  • #2

    New York University
    New York University

    New York, New York

    Key Differentiators

    • Public Health
    • Addiction Medicine

  • #3

    National Institutes of Health
    National Institutes of Health

    Bethesda, Maryland

    Key Differentiators

    • Public Health
    • Research Funding

  • #4

    Damien Center
    Damien Center

    Indianapolis, Indiana

    Key Differentiators

    • HIV Services
    • Harm Reduction

  • #5

    University of Michigan
    University of Michigan

    Ann Arbor, Michigan

    Key Differentiators

    • Public Health
    • Research

Original Source(s)

Projected Outcomes of Reducing Federal Funding for Syringe Service Programs via Executive Order

  • by Kirk B. Fetters, Pranav Padmanabhan, Kristina Yamkovoy, Xiaoyu Guan, Sarah E. Scott, Lauren Kerr, Kathleen Joseph, Gwenyth L. Day, Marina Plesons, Tyler S. Bartholomew, Hansel E. Tookes, Alia Al-Tayyib, Joshua A. Barocas

  • June 18, 2026

Related Content

Infant feeding decisions among people living with human immunodeficiency virus in the United States: a pilot study

CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.